adenine has been researched along with Lymphoma, B-Cell, Marginal Zone in 11 studies
Lymphoma, B-Cell, Marginal Zone: Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Splenomegaly is a common finding in chronic hepatitis B infection." | 1.42 | Remission of splenic marginal zone lymphoma in a patient treated for hepatitis B: a case of HBV-associated lymphoma. ( Huits, RM; Koot, AW; Visscher, AP, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Epperla, N | 2 |
| Zhao, Q | 1 |
| Chowdhury, SM | 1 |
| Shea, L | 1 |
| Moyo, TK | 1 |
| Reddy, N | 1 |
| Sheets, J | 1 |
| Weiner, DM | 1 |
| Geethakumari, PR | 1 |
| Kandarpa, M | 1 |
| Bruno, XJ | 1 |
| Thomas, C | 1 |
| Churnetski, MC | 1 |
| Hsu, A | 1 |
| Zurbriggen, L | 1 |
| Tan, C | 1 |
| Lindsey, K | 1 |
| Maakaron, J | 1 |
| Caimi, PF | 1 |
| Torka, P | 1 |
| Bello, C | 1 |
| Ayyappan, S | 2 |
| Karmali, R | 1 |
| Kim, SH | 1 |
| Kress, A | 1 |
| Kothari, S | 1 |
| Sawalha, Y | 1 |
| Christian, B | 1 |
| David, KA | 1 |
| Greenwell, IB | 1 |
| Janakiram, M | 1 |
| Kenkre, VP | 1 |
| Olszewski, AJ | 1 |
| Cohen, JB | 1 |
| Palmisiano, N | 1 |
| Umyarova, E | 1 |
| Wilcox, RA | 1 |
| Awan, FT | 1 |
| Alderuccio, JP | 1 |
| Barta, SK | 1 |
| Grover, NS | 1 |
| Ghosh, N | 1 |
| Bartlett, NL | 1 |
| Herrera, AF | 1 |
| Shouse, G | 1 |
| Zhou, H | 1 |
| Yang, L | 1 |
| Dang, Q | 1 |
| Huang, J | 1 |
| Cheng, Y | 1 |
| Zhang, Y | 1 |
| Shi, W | 1 |
| Furqan, F | 1 |
| Watson, G | 1 |
| Samaniego, F | 1 |
| Fayad, LE | 1 |
| Morrison, MW | 1 |
| Thompson, PA | 1 |
| Steiner, RE | 1 |
| Chi, L | 1 |
| Dabaja, B | 1 |
| Pinnix, CC | 1 |
| Neelapu, SS | 1 |
| Nastoupil, LJ | 1 |
| Strati, P | 1 |
| de Jong, J | 1 |
| Mitselos, A | 1 |
| Jurczak, W | 1 |
| Cordoba, R | 1 |
| Panizo, C | 1 |
| Wrobel, T | 1 |
| Dlugosz-Danecka, M | 1 |
| Jiao, J | 1 |
| Sukbuntherng, J | 1 |
| Ouellet, D | 1 |
| Hellemans, P | 1 |
| Noy, A | 2 |
| de Vos, S | 2 |
| Coleman, M | 2 |
| Martin, P | 2 |
| Flowers, CR | 2 |
| Thieblemont, C | 3 |
| Morschhauser, F | 2 |
| Collins, GP | 2 |
| Ma, S | 2 |
| Peles, S | 2 |
| Smith, SD | 1 |
| Barrientos, JC | 2 |
| Chong, E | 1 |
| Wu, S | 1 |
| Cheung, LW | 1 |
| Kwei, K | 1 |
| Hauns, B | 1 |
| Arango-Hisijara, I | 1 |
| Chen, R | 2 |
| Zhang, L | 1 |
| Nomie, K | 1 |
| Zhang, H | 1 |
| Bell, T | 1 |
| Pham, L | 1 |
| Kadri, S | 1 |
| Segal, J | 1 |
| Li, S | 1 |
| Zhou, S | 1 |
| Santos, D | 1 |
| Richard, S | 1 |
| Sharma, S | 1 |
| Chen, W | 1 |
| Oriabure, O | 1 |
| Liu, Y | 1 |
| Huang, S | 1 |
| Guo, H | 1 |
| Chen, Z | 1 |
| Tao, W | 1 |
| Li, C | 1 |
| Wang, J | 2 |
| Fang, B | 1 |
| Li, L | 1 |
| Badillo, M | 1 |
| Ahmed, M | 1 |
| Thirumurthi, S | 1 |
| Huang, SY | 1 |
| Shao, Y | 1 |
| Lam, L | 1 |
| Yi, Q | 1 |
| Wang, YL | 1 |
| Wang, M | 1 |
| Shana'ah, AY | 1 |
| Jones, D | 1 |
| Christian, BA | 1 |
| Maddocks, K | 1 |
| Woyach, JA | 1 |
| Koot, AW | 1 |
| Visscher, AP | 1 |
| Huits, RM | 1 |
| Smith, S | 1 |
| Smith, A | 1 |
| Munneke, B | 1 |
| Dimery, I | 1 |
| Beaupre, DM | 1 |
| Muñoz Bertrán, E | 1 |
| Pérez Ceballos, E | 1 |
| Gómez Espín, R | 1 |
| Ortega González, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Drug-Drug Interaction Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Subjects With B Cell Malignancy[NCT03301207] | Phase 1 | 25 participants (Actual) | Interventional | 2017-10-20 | Completed | ||
| A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma[NCT01980628] | Phase 2 | 63 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response[NCT04508647] | Phase 2 | 4 participants (Actual) | Interventional | 2020-11-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The DOR analyses is performed on the subset of subjects that achieve CR or PR as determined by IRC. DOR is calculated as the duration of time from the date of first response to the date of progression or death due to any cause. (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.
| Intervention | Months (Median) |
|---|---|
| Ibrutinib | NA |
"ORR is defined as the proportion of subjects who achieved complete response (CR), partial response (PR). Response criteria are as outlined in the International Working Group Criteria for NHL, Cheson (2007), with disease assessments performed by an independent review committee (IRC).~Per Cheson:~CR is defined as disappearance of all evidence of disease. PR is defined as regression of measurable disease and no new sites." (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.
| Intervention | Percentage of Participants (Mean) |
|---|---|
| Single Arm, Intent to Treat Population | 46 |
"Number of subjects that reached a complete response at the end of single agent induction as defined by a Lugano score of 3 or less on arm MONO - Monotherapy: Ublituximab.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake.~Patients who did not reach complete response at this point were then bridged to arm COMBO - Combotherapy: Ublituximab + Umbralisib." (NCT04508647)
Timeframe: 8 weeks post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
"Number of subjects that reached a complete response at up to 12 months post induction as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake." (NCT04508647)
Timeframe: up to 12 months post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
| Ublituximab First, Then Ublituximab and Umbralisib | 2 |
"Overall Response Rate for number of subjects as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Overall response rate assessed via PET CT utilizing Lugano deauvile criteria where lymphoma lesions had responded and would include complete response, partial response (> 50% improvement) and stable disease (less than 50 % response)" (NCT04508647)
Timeframe: up to 12 months post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
| Ublituximab First, Then Ublituximab and Umbralisib | 2 |
2 reviews available for adenine and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide | 2017 |
[Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
Topics: Adenine; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody | 2010 |
3 trials available for adenine and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Bupropion; Contrace | 2020 |
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.
Topics: Adenine; Biomarkers; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasm Recurrence | 2020 |
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia; Antineoplastic | 2017 |
6 other studies available for adenine and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.
Topics: Adenine; Cohort Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasm Recurrence, Local; Piperi | 2022 |
Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosp | 2020 |
Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.
Topics: Adenine; Central Nervous System; Humans; Lymphoma, B-Cell, Marginal Zone; Piperidines; Pyrazoles; Py | 2020 |
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Burkitt Lymphoma; Disease Models, Animal; Dru | 2017 |
Resistance mechanism for ibrutinib in marginal zone lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Bone Marrow; Drug Resistance, Neoplasm; Humans; | 2019 |
Remission of splenic marginal zone lymphoma in a patient treated for hepatitis B: a case of HBV-associated lymphoma.
Topics: Adenine; Bone Marrow; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunohistochemistry; Lymphom | 2015 |